Michael Schmidt
Stock Analyst at Guggenheim
(3.55)
# 917
Out of 4,734 analysts
79
Total ratings
52.73%
Success rate
5.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Maintains: Buy | $80 → $78 | $34.63 | +125.24% | 1 | Jan 8, 2025 | |
| EXEL Exelixis | Maintains: Buy | $33 → $42 | $36.20 | +16.02% | 8 | Jan 7, 2025 | |
| ARVN Arvinas | Reiterates: Buy | n/a | $18.05 | - | 2 | Dec 12, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $1.83 | +446.45% | 3 | Dec 12, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Buy | n/a | $110.05 | - | 2 | Dec 11, 2024 | |
| TARA Protara Therapeutics | Reiterates: Buy | $20 | $4.55 | +339.56% | 1 | Dec 6, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $39.45 | +181.37% | 2 | Dec 5, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $82 → $87 | $40.29 | +115.93% | 2 | Dec 3, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $12 → $8 | $2.24 | +257.14% | 3 | Nov 15, 2024 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $4 → $3 | $0.58 | +417.33% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.02 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $5.33 | +143.90% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $92 | $71.93 | +27.90% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.03 | +296.04% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.51 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $9.99 | +250.35% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.02 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.62 | +1,031.59% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.82 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $19.24 | +76.72% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $13.08 | +221.10% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.91 | +2,101.67% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 | $9.58 | +56.58% | 3 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.80 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.85 | +1,251.35% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.66 | +430.50% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $4.12 | +530.76% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.48 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.35 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $32.42 | +146.76% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.15 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.20 | +71.88% | 2 | Nov 7, 2017 |
SpringWorks Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $80 → $78
Current: $34.63
Upside: +125.24%
Exelixis
Jan 7, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $36.20
Upside: +16.02%
Arvinas
Dec 12, 2024
Reiterates: Buy
Price Target: n/a
Current: $18.05
Upside: -
ADC Therapeutics
Dec 12, 2024
Reiterates: Buy
Price Target: $10
Current: $1.83
Upside: +446.45%
Blueprint Medicines
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $110.05
Upside: -
Protara Therapeutics
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $4.55
Upside: +339.56%
Merus
Dec 5, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $39.45
Upside: +181.37%
Revolution Medicines
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $40.29
Upside: +115.93%
Zentalis Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.24
Upside: +257.14%
Adaptimmune Therapeutics
Nov 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.58
Upside: +417.33%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $29.02
Upside: -
Sep 30, 2024
Initiates: Buy
Price Target: $13
Current: $5.33
Upside: +143.90%
Sep 16, 2024
Maintains: Buy
Price Target: $86 → $92
Current: $71.93
Upside: +27.90%
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $3.03
Upside: +296.04%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.51
Upside: -
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $9.99
Upside: +250.35%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.02
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.62
Upside: +1,031.59%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.82
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $19.24
Upside: +76.72%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $13.08
Upside: +221.10%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.91
Upside: +2,101.67%
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $9.58
Upside: +56.58%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $20.80
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.85
Upside: +1,251.35%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $5.66
Upside: +430.50%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $4.12
Upside: +530.76%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $8.35
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $32.42
Upside: +146.76%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $7.15
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.20
Upside: +71.88%